Tesla denies further Model 3 production issues
A Tesla Model 3 is seen in a showroom in Los Angeles, California U.S. January 12, 2018. REUTERS/Lucy Nicholson
Get Alerts TSLA Hot Sheet
Join SI Premium – FREE
(Reuters) - Tesla Inc (NASDAQ: TSLA) is on track to achieve its production targets for the Model 3, the electric car-maker said on Thursday, squashing a report of further delays and quality issues for its latest and most-affordable sedan.
Tesla's problems with battery production at its Gigafactory in Sparks, Nevada, are worse than it had acknowledged, CNBC had reported earlier in the day, citing some company employees.
The problems included Tesla needing to make some batteries by hand and borrowing scores of employees from one of its suppliers to help with manual assembly, CNBC had said.
Tesla shares closed down 2.4 percent on Thursday following the report, but rose 1.6 percent in extended trading after the company said it had no further production setbacks.
"To be absolutely clear, we are on track with the previous projections for achieving increased Model 3 production rates that we provided earlier this month," a Tesla spokesman said in a e-mailed statement.
"As has been well documented, until we reach full production, by definition some elements of the production process will be more manual," the spokesman said.
Earlier this month, Tesla delayed a production target for the Model 3 for the second time, disappointing investors even as it claimed "major progress" overcoming manufacturing challenges that have hampered the vehicle's rollout.
Tesla currently plans to make about 2,500 Model 3s per week by the end of the first quarter, half the number it had earlier promised. It expects to reach its goal of 5,000 vehicles per week by the end of the second quarter.
(Reporting by Aishwarya Venugopal in Bengaluru; Editing by Savio D'Souza)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla (TSLA) PT Raised to $500 at RBC Capital on 'Potential SpaceX Combination'
- Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
- Active options: TSLA NVDA AAPL AMZN SPCX MSFT INTC MU META SOFI
Create E-mail Alert Related Categories
Corporate News, Guidance, Reuters, Trader TalkRelated Entities
Tesla, Model 3Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share